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• ICER is the first major nonprofit US group to engage stakeholders in a public discourse about drug effectiveness and affordability • Our analysis does not reveal the validity of stakeholder comments but suggests that manufacturers, providers, patients, government, and plans are actively responding to the reports, particularly about modeling methods and additional available data
FUNDING DISCLOSURE
This study was unfunded.
• At the time of the analysis, three assessments were completed and had public comments available for review; we analyzed written public comments to ICER on these reports: -Sacubitril/valsartan (heart failure; HF) 3 -PCSK9 inhibitors (hypercholesterolemia) 4 -New hepatitis C drugs (simeprevir, sofosbuvir) 5
Figure 1. Value Assessment Framework
• 100 comments were made in 27 unique correspondences -49% Hepatitis C -46% PCSK9 -5% HF • The mean (SD) total comments per correspondence was 4.5 (4.3) • Disagree with definition of heterozygous familial hypercholesterolemia • Disagree with goal LDL-C level in heterozygous familial hypercholesterolemia • Model does not include all treatment strategies for familial hypercholesterolemia subgroups • Model does not account for efficacy differences between treatments in patient subgroups • Model does not account for treatment success in people with longstanding undiagnosed disease Efficacy assumptions (5, 7.4%)
• Challenged assumption about product efficacy in subgroups • Inconsistent assumptions regarding ezetimibe and LDL-lowering efficacy
